|
Feb 7
|
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
|
|
Feb 7
|
CORRECTED-UPDATE 2-US FDA puts hold on Gilead's blood cancer therapy trials
|
|
Feb 7
|
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
|
|
Feb 7
|
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2023 Earnings Call Transcript
|
|
Feb 7
|
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
|
|
Feb 6
|
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Feb 6
|
Gilead Earnings Meet Expectations as It Seeks Recovery From Cancer Drug Stumble
|
|
Feb 6
|
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
|
|
Feb 6
|
UPDATE 2-Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO
|
|
Jan 26
|
How To Invest: The Slow Saucer Base Can Produce Quick Returns
|
|
Jan 24
|
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
|
|
Jan 23
|
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
|
|
Jan 23
|
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
|
|
Jan 23
|
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
|
|
Jan 23
|
Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer
|
|
Jan 23
|
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
|
|
Jan 23
|
UPDATE 3-US FDA requires 'boxed warning' for CAR-T cancer therapies
|
|
Jan 23
|
US FDA requires 'boxed warning' for CAR-T cancer therapies
|
|
Jan 22
|
Why Gilead Sciences Stock Got Mashed on Monday
|
|
Jan 22
|
Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction?
|